NCT00510289View on ClinicalTrials.gov

Sorafenib in Myelodysplastic Syndrome

PHASE2TerminatedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic

Interventions

DRUG

Sorafenib

400 mg twice a day until progression or unacceptable toxicity develops.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Duke University

OTHER

NCT00510289 - Sorafenib in Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter